The wire — 13 November 2026

Thursday, 13 November — Armistice Day silenced Wednesday's desks, and three strong rounds that announced on the 12th make their way into print today alongside two fresh-dated deals. Five rounds in total, anchored by a Paris cancer biotech that wants to change how the pharmaceutical industry tests drugs before they reach patients.

Three of today's deals share a structure worth naming before it becomes a trope: AI applied to prediction in domains where the feedback loop has historically been too slow and too expensive to run at the pace the work demands. Nebuly measures whether enterprise AI is delivering what CFOs expect; Orakl Oncology predicts how cancer drugs will behave in individual patients before entering clinical trials; Biomatter designs industrial enzymes that conventional screening methods would take years to find. The other two — Gama and Well — don't share this thread, but each stands on its own logic: satellite power infrastructure and SME financial automation are different problems with the same clarity of purpose.

---

Orakl Oncology raises $34M (€31M) Series A — Paris, France. Co-led by Norrsken VC and Singular, with InfraVia, Serena, Bpifrance (Patient Autonome Fund), teampact.ventures, Plug and Play, Verve Ventures, Speedinvest, and returning investor HCVC. Thomas Wolf (Hugging Face co-founder) and Stan Polu among the angels. Founded in 2023 by Fanny Jaulin (CEO), Gustave Ronteix, and Diane-Laure Pagès — spun out of Institut Gustave Roussy — Orakl builds patient-derived tumour organoids combined with AI to predict how cancer drugs behave in individual patients before clinical trials begin. The €31M funds a fivefold expansion of lab data generation capacity, extensions into lung and gastric cancer, and commercial teams in the US and UK. Singular's co-lead is the week's notable repeat: the fund also led Sumary's $25M seed on Monday — two AI-meets-domain-expertise bets written in the same week, in sectors as different as accounting and oncology.

Nebuly raises €19M ($21M) Series A — Turin, Italy. Led by Planven (Zürich), with Exor Ventures, Tenacity Capital, TGVG Capital, Founders Factory, and CDP Venture Capital (AI Fund and Digital Transition Fund, backed by EU NextGenerationEU). Carry-forward from Wednesday's edition: the round had one source when Wednesday closed; it now has four. Founded in 2022 by Francesco Signorato and Diego Fiori, Nebuly connects to enterprise AI agents deployed inside organisations and measures their real business impact — revenue influenced, time saved, decisions supported — rather than query volume. Named customers include Oura, Iveco Group, CNH, and Zeiss; contracts reportedly start at $100,000 per year. The €19M funds US and European go-to-market expansion and grows headcount from 40 to 60.

Biomatter raises $18M (€16.2M) Series A — Vilnius, Lithuania. Led by Astanor, with UVC Partners, Inventure, and Metaplanet. Founded in 2018 by Laurynas Karpus, Vykintas Jauniškis, and Irmantas Rokaitis — all from Vilnius University's Institute of Biotechnology, EPO Young Inventors Prize alumni. Biomatter designs industrial enzymes from scratch using generative AI — de novo protein design rather than modification of natural enzymes — with named customers including AstraZeneca, BASF, Sanofi, Tereos, and Thermo Fisher Scientific. Approximately half of its 25+ enterprise customers are US-based. The $18M funds a 2,000 m² design-and-testing lab in Vilnius (opening 2027) and a larger US commercial team.

Gama raises €15M seed — Paris, France (manufacturing at Ivry-sur-Seine). Led by Transition, with Planet A, Draper Associates, and Manta Ray. Founded in 2022 by Andrew Nutter (CEO), Louis de Gouyon Matignon, and Thibaud Elzière. Gama designs and manufactures Wing — a deployable solar array for satellites, built to fit standard rocket fairings while delivering the power output next-generation spacecraft require. The €15M establishes the Wing production line at Ivry-sur-Seine and funds approximately 60 engineering hires. Transition's backing frames this as an infrastructure play within the energy transition: the satellites that underpin methane monitoring, low-orbit broadband, and precision agriculture all need more power than current arrays reliably provide.

Well raises $4M (€3.6M) pre-seed — Paris, France. Led by Speedinvest, with Kima Ventures, Purple, OPRTRS Club, Relics Ventures, Source Ventures, and 199 Ventures. Founded in 2025 by Maxime Champoux (CEO, ex-Qonto product and growth, seven years) and Bastien Blanc (CTO, ex-Fintecture VP Engineering). Well builds an AI bookkeeping assistant for small businesses that connects banking, accounting software, invoicing, email, and CRM into a persistent financial layer — processing 700,000+ records in production before this close. France's mandatory B2B e-invoicing reform (rolling out progressively through 2027) is the near-term demand catalyst; Kima Ventures has previously backed Cleavr and ZML in this archive.

---

Skipped this edition: SE3 Labs (Munich, $30M Series A, Accel lead) — excluded: the company builds spatial AI explicitly for military autonomous drones and has existing Bundeswehr contracts. triPica (Paris, €12.4M, energy billing SaaS) — announced 10 November, three days before today's window, and slipped past two consecutive editions; stage is not explicitly stated in primary sources. Kardi Ai (Czech Republic, €5.3M Series A, AI cardiac wearable) and Anorak (London, $5M pre-seed, interactive generative video) — both announced 11 November, two days before today's window; both solid rounds that may carry forward if no edition has covered them by tomorrow.